Held by 3 specialist biotech funds
High Convergence**Signal Note: OrbiMed Initiates $55.2M Position in Corvus Pharmaceuticals** OrbiMed's entry into CRVS likely reflects confidence in the company's pipeline, particularly CPI-444 (atezolizumab + ciforadenant) combinations in checkpoint inhibitor-resistant tumors where adenosine pathway blockade shows clinical rationale.
AI analyst context — unlock full analysis
# Signal Note: Perceptive Advisors Initiates CRVS Position Edelman's $5.3M entry into Corvus likely reflects conviction in the company's lead asset CPI-444 (atezolizumab + CPI-444), an IDO1 inhibitor in combination with Roche's checkpoint inhibitor for multiple indications including non-small cell lung cancer and renal cell carcinoma. The timing suggests positioning ahead of near-term clinical readouts, potentially including ECHO-301/302 trial data expected in 2024-2025 that could validate the combination's efficacy in reducing resistance to anti-PD-L1 therapy. Given Edelman's track record with clinical-stage immunotherapy plays, this signals confidence in the mechanism and trial design despite IDO1's mixed historical performance as a monotherapy.
+ 1 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial